Finoriq research workspace
Altimmune, Inc. (ALT) Historical Metrics
Review reported fundamentals, derived ratios, valuation context, and historical charts for Altimmune, Inc. (ALT).
Company Snapshot
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
- Company
- Altimmune, Inc. (ALT)
- Ticker
- ALT
- Market Cap
- $548.4M
- Latest Price
- $2.82
- Industry
- Biotech & Pharma
Altimmune, Inc. (ALT) Current Valuation Metrics
Static valuation preview for Altimmune, Inc. (ALT). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 14,704x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -15.1% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -11.9% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 2.12x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.